Canada’s Drug Agency | Drugs, Health Technologies and Systems.

nivolumab and ipilimumab

Details

Generic Name:
nivolumab and ipilimumab
Project Status:
Received
Therapeutic Area:
Unresectable or metastatic MSI-H or dMMR colorectal cancer
Manufacturer:
Bristol Myers Squibb Canada Co.
Call for patient/clinician input open:
Brand Name:
Opdivo and Yervoy
Project Line:
Reimbursement Review
Project Number:
PC0396-000
Call for patient/clinician input closed:
Tumour Type:
Gastrointestinal
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Opdivo (nivolumab), in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Opdivo (nivolumab), in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open11-Feb-25
Call for patient/clinician input closed07-Apr-25
Submission received26-Mar-25
Submission accepted-
Last Updated : March 26, 2025